Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals.
Biron
F
F
Service des Maladies Infectieuses et Tropicales, Hôpital de la Croix Rousse, Lyon, France.
Lucht
F
F
Peyramond
D
D
Fresard
A
A
Vallet
T
T
Nugier
F
F
Grange
J
J
Malley
S
S
Hamedi-Sangsari
F
F
Vila
J
J
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000009:adverse effects* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005602:France; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000254:growth & development; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects* / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000821:virology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012367:RNA, Viral / Q000097:blood
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D012367:RNA, Viral; D016049:Didanosine; D006918:Hydroxyurea